GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (FRA:8SJ) » Definitions » Payments of Debt

Shanghai Junshi Biosciences Co (FRA:8SJ) Payments of Debt : €-61.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shanghai Junshi Biosciences Co Payments of Debt?

Shanghai Junshi Biosciences Co's Payments of Debt for the six months ended in Dec. 2023 was €-46.8 Mil.

Shanghai Junshi Biosciences Co's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was €-61.8 Mil.

Shanghai Junshi Biosciences Co Payments of Debt Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Payments of Debt Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Payments of Debt
Get a 7-Day Free Trial -178.26 -50.46 -110.23 -15.36 -61.76

Shanghai Junshi Biosciences Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.82 -0.71 -14.68 -15.04 -46.78

Shanghai Junshi Biosciences Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-61.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Junshi Biosciences Co Payments of Debt Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (FRA:8SJ) » Definitions » Payments of Debt
Comparable Companies
HKSE:01548 HKSE:09926 HKSE:09995 HKSE:01177 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 HKSE:09969 HKSE:01801 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
01877:Hong Kong 688180:China
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Website
https://www.junshipharma.com
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co Headlines

No Headlines